## Maximizing the Value of New Products 

To derive the greatest value from new products, we are focusing on maximizing the overactive bladder (OAB) franchise; building a business base in the field of oncology; launching new products on an ongoing basis worldwide; and reinforcing our sales operations in emerging markets. 

## Maximizing the OAB Franchise 

Vesicare is one of the leading branded prescription drugs on the market for OAB treatments. We have also begun the global introduction of mirabegron (generic name), which provides a new therapeutic option in OAB as the result of its different mechanism of action to Vesicare. Mirabegron is now available in over 25 countries around the world. Going forward, while focusing even more on achieving market penetration with mirabegron, we will maximize the OAB franchise. 

continuous product introductions (Approvals and launches from April 2013 to July 2014) 

## EMEA 

## Approved/Launched 

• XTANDI • VESOMNI 

## Asia & Oceania 

## Approved/Launched 

• XTANDI (South Korea, Australia) 

• BETMIGA (Hong Kong, South Korea, Taiwan, Australia) 

• Eligard (Hong Kong, Thailand, Vietnam, Singapore, Taiwan, Malaysia) 

• MYCAMINE (Australia, Malaysia, Singapore) 

• Prograf XL/Advagraf (Indonesia, the Philippines) 

## New indications 

• MYCAMINE (Hong Kong) 

## The Oncology Field as a Future Growth Driver 

We are working to establish oncology as our third GCL area next to urology and transplantation. We are building up our business base in this field in various regions, and steadily starting up our operations with the prostate cancer treatment XTANDI as the key driver of growth. XTANDI is sold in over 25 countries worldwide. Currently we are conducting clinical trials in earlier stages of prostate cancer than current indication and breast cancer. Looking ahead, we plan to launch XTANDI in more countries, while also seeking to expand the range of indications for the drug to maximize its value. 

## Japan 

## Approved/Launched 

• Micamlo BP • Irribow OD Tablet •Acofide • Suglat • Bisono Tape • XTANDI 

## New indications 

• Prograf • Dormicum 

## The Americas 

Launched 

• XTANDI (Canada, Argentina) 

• Myrbetriq (Canada) 

• ASTAGRAF XL (U.S.) 

## New indications 

• Tarceva (U.S.) 

• MYCAMINE (U.S.) 

